Skip to main content
      RT @drdavidliew: Wasn’t following the SLE stuff #EULAR2023 but heard a lot of talk about both telitacicept & CAR-T

      David Liew drdavidliew

      1 year 4 months ago
      Wasn’t following the SLE stuff #EULAR2023 but heard a lot of talk about both telitacicept & CAR-T, including meeting highlights by Christian Dejaco. Both look pretty exciting - the longer the sustained remission with CAR-T, the more it looks like maybe the real deal @RheumNow https://t.co/oKzb8ojTcz
      RT @Yuz6Yusof: #EULAR2023 Clinical Highlights. Osteoarthritis. OP0071 Single centre Phase 2 RCT showed Denosumab halted

      Md Yuzaiful Md Yusof Yuz6Yusof

      1 year 4 months ago
      #EULAR2023 Clinical Highlights. Osteoarthritis. OP0071 Single centre Phase 2 RCT showed Denosumab halted erosion in Erosive OA at 24 weeks treatment, and the treatment effect enhances after 48 weeks vs PBO @RheumNow https://t.co/YWFUg3cp7P
      Tune it at 1pm EST for RheumNow's daily #EULAR23 recaps. You can find us live on YouTube, Twitter and LinkedIn. https:/

      Dr. John Cush RheumNow

      1 year 4 months ago
      Tune it at 1pm EST for RheumNow's daily #EULAR23 recaps. You can find us live on YouTube, Twitter and LinkedIn. https://t.co/i8rm5t8mFS
      RheumNow’s expanded coverage of the #EULAR2023 annual meeting is sponsored in part by Bristol Myers Squibb. All conten

      Dr. John Cush RheumNow

      1 year 4 months ago
      RheumNow’s expanded coverage of the #EULAR2023 annual meeting is sponsored in part by Bristol Myers Squibb. All content is chosen by RheumNow and its faculty.
      RT @bella_mehta: Depositions of crystals in coronary arteries were associated with MACE @rheumnow #EULAR2023 https://t.c

      Bella Mehta bella_mehta

      1 year 4 months ago
      Depositions of crystals in coronary arteries were associated with MACE @rheumnow #EULAR2023 https://t.co/VHxtsB7ZsA
      RT @AurelieRheumo: Adherence to TNFi follows different trajectories

      Cluster 1: “moderate then high” 51%
      Cluster 2:

      Aurelie Najm AurelieRheumo

      1 year 4 months ago
      Adherence to TNFi follows different trajectories Cluster 1: “moderate then high” 51% Cluster 2: “moderate then low” 20% Cluster 3: “low adherence, to discontinuation” 18% Cluster 4: “low then high adherence” 11% Most demographic & clinical features CAN NOT predict trajectory! https://t.co/4wLg6b70Kl
      RT @drdavidliew: @eular_org recommendations session #EULAR2023 - and the first recommendation is one I’m so glad is up

      David Liew drdavidliew

      1 year 4 months ago
      @eular_org recommendations session #EULAR2023 - and the first recommendation is one I’m so glad is up front: Adult Onset Still’s Disease (AOSD) and Systemic JIA (sJIA) are the same disease. If anything, it’s the really young sJIA (<18 months old) which is different @RheumNow https://t.co/OCDeeNtNoR
      RT @drdavidliew: @eular_org recommendation for AOSD/sJIA:
      An IL-1 or IL-6 inhibitor should be initiated as early as poss

      David Liew drdavidliew

      1 year 4 months ago
      @eular_org recommendation for AOSD/sJIA: An IL-1 or IL-6 inhibitor should be initiated as early as possible when the diagnosis is established #EULAR2023 @RheumNow https://t.co/xNUdpGDxb9
      RT @Yuz6Yusof: #EULAR2023 #POS1156 Previous case series reported ~9% de novo nephritis in #SLE pts treated with belimuma

      Md Yuzaiful Md Yusof Yuz6Yusof

      1 year 4 months ago
      #EULAR2023 #POS1156 Previous case series reported ~9% de novo nephritis in #SLE pts treated with belimumab for non-renal lupus. Post-hoc analysis of 5 BEL Non-LN RCTs showed 8% had de novo LN. Risk increased in Asians but lowered with low dose BEL or s/c form @RheumNow https://t.co/GqAr3tppWh
      RT @drdavidliew: One new overarching principle for @eular_org PsA recommendations:

      “The choice of treatment should ta

      David Liew drdavidliew

      1 year 4 months ago
      One new overarching principle for @eular_org PsA recommendations: “The choice of treatment should take account of safety considerations regarding individual MoA to optimize the benefit-risk profile” Wonder what triggered that #EULAR2023 #oralsurveillance @RheumNow https://t.co/19BfJQz4Za
      RT @synovialjoints: The incidence of MACEs at 8 years is low in AS patients treated with NSAIDs. Study of 22929 patients

      Dr. Antoni Chan synovialjoints

      1 year 4 months ago
      The incidence of MACEs at 8 years is low in AS patients treated with NSAIDs. Study of 22929 patients, NSAIDs (SHR: 0.40 [0.32-0.49], p<0.001) and anti-TNFs (SHR: 0.61 [0.47-0.81], p<0.001) associated with a lower risk of MACE, Fakih O, Abst#POS0301, #EULAR2023 @RheumNow https://t.co/i5GZMcJwyO
      RT @drdavidliew: New 2023 @eular_org SLE recommendations

      Key changes, in response to evidence:
      - more caution re: stero

      David Liew drdavidliew

      1 year 4 months ago
      New 2023 @eular_org SLE recommendations Key changes, in response to evidence: - more caution re: steroids - biologics earlier - combo therapy (BEL or CNI/VCS) considered for lupus nephritis #EULAR2023 @RheumNow https://t.co/J3Lp8owRyT
      RT @drdavidliew: Key points from #EULAR2023 on how to manage SLE
      @RheumNow https://t.co/vJy7Cg7w8N

      David Liew drdavidliew

      1 year 4 months ago
      Key points from #EULAR2023 on how to manage SLE @RheumNow https://t.co/vJy7Cg7w8N
      RT @synovialjoints: Late Breaker - EULAR 2023 update on imaging of large vessel vasculitis. Ultrasound is now recommende

      Dr. Antoni Chan synovialjoints

      1 year 4 months ago
      Late Breaker - EULAR 2023 update on imaging of large vessel vasculitis. Ultrasound is now recommended as first line imaging test in all patients with suspected GCA, and axillary arteries should be in the standard examination, Dejaco C et al, Abst#LB0009, #EULAR2023 @RheumNow https://t.co/ya41nJG6qK
      RT @Janetbirdope: #ClinicalPearl This is cool - think of SGLT2 for #lupus #nephritis? presented at #SLE recommendations

      Janet Pope Janetbirdope

      1 year 4 months ago
      #ClinicalPearl This is cool - think of SGLT2 for #lupus #nephritis? presented at #SLE recommendations ⁦@RheumNow⁩ #EULAR2023 ⁦@eular_org⁩ https://t.co/8mbNt2n64v